Related Experiment Video

Updated: Jul 18, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Ovarian cancer vaccine trials and tribulations

Ronald J Buckanovich1

  • 1University of Michigan Comprehensive Cancer Center, Division of Hematology-Oncology and Division of Gynecologic Oncology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA. ronaldbu@umich.edu

Expert Opinion on Biological Therapy
|December 8, 2006
PubMed

Insights

Solid tumor vaccine therapy shows promise. Recent trials report improved survival in breast and prostate cancers, with advancements in ovarian cancer vaccines targeting antigens and overcoming immunosuppression.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccinology

Background:

  • Solid tumor vaccine therapy has faced historical challenges with numerous failed trials.
  • Recent advancements indicate a turning point, with initial positive human trials emerging.
  • Progress has been observed in breast and prostate cancer vaccine trials, showing improved survival outcomes.

Purpose of the Study:

  • To review recent developments in ovarian cancer vaccine therapy.
  • To address strategies for enhancing the efficacy of tumor vaccines.
  • To explore future directions in ovarian cancer vaccine research.

Main Methods:

  • Summarizing recent clinical trials of ovarian cancer vaccines.
  • Analyzing improvements in tumor vaccine target antigens and antigen presentation.
  • Investigating mechanisms of tumor-associated immunosuppression.
  • Identifying biological therapies to augment vaccine effectiveness.

Main Results:

  • While no Phase III ovarian cancer vaccine trials have reported positive results yet, significant progress has been made.
  • Improvements in target antigens and antigen presentation are enhancing vaccine potential.
  • Understanding and addressing tumor-induced immunosuppression are key areas of advancement.

Conclusions:

  • Ovarian cancer vaccine therapy is progressing, despite past setbacks.
  • Advances in antigen targeting, presentation, and overcoming immunosuppression are crucial for future success.
  • Combination with biological therapies may improve overall vaccine efficacy in ovarian cancer.

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.